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Ghent, Ghent, Belgium; 3Pﬁzer s.r.o, Prague, Czech RepublicA B S T R A C TObjectives: To compare data requirements and their availability for
health economic (HE) evaluations in ﬁve countries in Central/Eastern
Europe (CEE) (Poland, the Czech Republic, Slovakia, Hungary, and
Romania) and ﬁve countries in Western Europe (WE) (the United
Kingdom, France, Germany, The Netherlands, and Sweden). Methods:
A questionnaire was developed and distributed to market access
personnel from Pﬁzer who were asked to complete the questionnaire
either from their own knowledge or with support of external experts.
The questionnaire focused on the obligation to conduct HE assess-
ment for reimbursement submissions, local HE guidelines, applied
discount rates for future costs and effects, willingness-to-pay thresh-
olds, and available data sources. Results: HE is mandatory in all CEE
and three WE participating countries for reimbursement applications
of innovative drugs. Usually, cost-effectiveness analysis and budget-
impact analyses are required. The preferred outcome of cost-
effectiveness analysis is quality-adjusted-life years. In Romania,
France, and the Czech Republic, guidelines could not be identiﬁed at
the time of the survey. The applicant usually prepares HE evaluations;
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ndence to: Jana Skoupá, Pod Šmukýrˇkou 2, 150 00unlocked models have to be presented for scrutiny. Discount rates
vary from 1.5% to 5%, and, usually, is the same for costs and outcomes
(except in The Netherlands and Poland). Only the United Kingdom,
Poland, and Slovakia have an explicit willingness-to-pay threshold. In
Poland, it is based on the gross domestic product per capita, and in
Slovakia, it is based on multiples of average monthly salary. Differ-
ences were found on data availability. In WE, data can be acquired
easier than in CEE. Health insurance funds do not provide their data
unless they were published. Patient registries are either not available
in CEE or difﬁcult to access, so applicants mostly rely on retrospective
medical chart data, hospital information systems, or expert panels.
Conclusions: We found similar requirements for HE analyses in CEE
and WE but differences in data availability. This results in less
accurate inputs across the CEE, inﬂuencing analyses’ outcomes.
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The continuous inﬂux of health care technologies across European
Union (EU) member states together with limited ﬁnancial resources
have put more emphasis on identifying those innovations provid-
ing best value for money. Structured health technology assessment
(HTA) has therefore been implemented across Europe. Cost-
effectiveness (CE) and also budget impact (BI) analyses represent
an important part of HTA in most of the countries, including
Central and Eastern European (CEE) countries. Hence, not surpris-
ingly, CE and BI analyses are rapidly emerging in these countries.
But CE studies and BI analyses require data, and the general
feeling is that such data are much less available in CEE countries
than in Western European (WE) countries. We conducted a
survey among 10 CEE and WE member states, with the aim of
comparing data requirements and their availability for health
economic (HE) evaluations.Methods
A total of 10 countries participated in the survey, ﬁve represent-
ing Central and Eastern Europe (the Czech Republic, Hungary,
Poland, Romania, and Slovakia) and ﬁve representing Western
Europe (France, Germany, The Netherlands, Sweden, and the
United Kingdom). The project was supported by an educational
grant from Pﬁzer.
A common 11-item questionnaire was developed and sent out
to participating countries (see Appendix 1 found in Supplemental
Materials found at http://dx.doi.org/10.1016/j.vhri.2014.06.003).
Health economics and outcomes research representatives
from Pﬁzer in individual countries were asked to complete the
questionnaire either from their own knowledge or with the
support of local experts. Data obtained were synthesized and
rechecked locally by local experts in HTA to avoid bias or
misinterpretations.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
conﬂicts of interest with regard to the content of this article.
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bursement submission.2. Presence/absence of an ofﬁcial HTA agency.
3. CE and/or BI analyses included/not included in legislation.
4. Methodological guidelines for CE analyses present/absent.
5. Presentation of unlocked CE models to decision makers
obligatory/optional.
6. Required perspective of CE analyses—health care/societal.
7. Discount rate for costs and beneﬁts in CE analyses.
8. Choice of the comparator used in the CE analyses.
9. CE threshold.
10. Availability of data sources used in CE and BI analyses
including epidemiology, resource utilization, and costs.
11. Unavailable or difﬁcult to obtain data necessary for CE and BI
analyses; ways how to overcome missing data.Table 1 – Commonly used discount rates for costs
and beneﬁts.
Countries Discount rates for future costs and
health beneﬁts (%)
Health effects Future costs
The Netherlands 1.5 4
The United Kingdom 3.5 3.5
Sweden 3 3
France NA NA
Germany Not deﬁned Not deﬁned
Romania Not deﬁned Not deﬁned
Poland 3.5 5
Hungary 3.7 3.7
The Czech Republic 3 3
Slovakia 5 5
NA, not available/applicable.Results
CE analysis is a mandatory part of the HTA for innovative drugs
in all CEE and three of the participating WE countries (The
Netherlands, the United Kingdom, and Sweden). BI analysis is
usually also required, with the exception of Romania and Swe-
den, where only CE analysis is mandatory.
All survey participants from WE countries have an ofﬁcial
HTA agency, a review body that reviews and/or produces and
disseminates assessment reports on medical technologies. Most
of the agencies are governmental institutions. In the CEE region,
only Poland and Hungary reported an ofﬁcial and functioning
governmental agency (note that during 2013, Romania estab-
lished a formal HTA agency at the Ministry of Health). In addition
Poland has several private entities that focus on providing not
only HTA reports, systematic reviews, data collection, and eval-
uation but also training and educational activities.
With the exception of Germany, HE is included in the
legislation of all participating CEE and WE countries, usually as
a part of a complex HTA process. In France, the reimbursement
decision is currently mainly based on the medical beneﬁt of the
assessed intervention; for the pricing decision, BI is taken into
account. Furthermore, CE data are required only during reassess-
ment after a product is launched. Changes are, however, dis-
cussed; that is, CE should be included into the assessment and
appraisal process upfront. In most of the other countries, CE is an
important parameter for the reimbursement decision (the United
Kingdom, Poland, The Netherlands, Sweden, the Czech Republic,
and Slovakia). Besides the clinical evaluation (safety, efﬁcacy, and
effectiveness) of the assessed technology, its BI and CE are
usually considered before reimbursement is granted. Quality-
adjusted-life years (QALYs) seem to be the preferred outcome in
CE analyses not only in WE countries (the United Kingdom, The
Netherlands, and Sweden) but also in several CEE countries
(Poland, Slovakia, Hungary, and the Czech Republic).
Not all countries applying HE evaluations in the decision-
making process follow local guidelines for HE analyses. In
Romania and the Czech Republic, ofﬁcial guidelines could not
be identiﬁed at the time of the survey (note that in 2013, CE and
BI guidelines were published in the Czech Republic by the local
pricing and reimbursement authority).
Reimbursement ﬁles that include HE evaluations are usually
prepared by the applicant (industry) and submitted to local
agencies. In Sweden, the United Kingdom, The Netherlands,
and Poland, full, unlocked models have to be presented for
scrutiny. In CEE countries except Poland, the presentation of
models is not obligatory, but when they are used they have to bedescribed in detail and applicants might be asked for clariﬁcation
or additional information requested by authorities. Differences
also exist in the communication between applicants and author-
ities during the HTA process across countries. While in several
countries, applicants are given the opportunity to present HE
results to a multidisciplinary committee (Slovakia) or clarify
uncertainties in written form (the United Kingdom and Poland),
other agencies do not organize hearings (the Czech Republic, The
Netherlands, Romania, Poland, and Hungary). In Sweden, appli-
cants might be invited in speciﬁc situations, while in The Nether-
lands scientiﬁc advice might be obtained before submitting an
ofﬁcial reimbursement dossier.
Only 4 of the 10 countries require a comprehensive societal
perspective in the CE analysis (The Netherlands, Sweden, France,
and Poland); however, in other countries, societal costs are
optional (Romania and the Czech Republic), without an impact
on the decision.
The most common annual discount rate used in the CE
baseline scenario varies between 1.5% and 5% (Table 1) and, with
the exception of The Netherlands and Poland, is the same for
costs and outcomes.
One of the crucial parts of the CE analysis is the comparator’s
choice because all countries use a comparative assessment. In
most countries, the comparator is the standard intervention,
which is expected to be replaced by the new technology (The
Netherlands, the United Kingdom, Sweden, Poland, Hungary, and
Slovakia) or the most cost-effective technology, if more compa-
rators can be considered. In some countries, the comparator is
either not speciﬁed (the Czech Republic, France, and Romania) or
explicitly identiﬁed by authorities (Germany). Although prelimi-
nary advice on comparator selection is possible in some countries
(e.g., The Netherlands), the ﬁnal decision on the appropriate
comparator’s choice is made during the HTA process (Germany,
The Netherlands, Sweden, and the Czech Republic).
Only three of the assessed countries have an explicit
willingness-to-pay (WTP) threshold. In the United Kingdom, the
threshold of £20000 to £30000 is currently applied with some
exceptions (e.g., end-of-life interventions). In Slovakia, a WTP
threshold based on multiples of average monthly wage was
introduced and is included in legislation. If interventions prove
an incremental cost-effectiveness ratio of less than 24 average
wages (€18,500/QALY), they are considered as cost-effective and
quite likely to be included into reimbursement lists. The range of
24 to 35 average monthly wages (about €27,000/QALY) enables
conditional reimbursement for 2 years with an agreed budget
cap. Technologies with a higher incremental cost-effectiveness
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In Poland, the CE threshold is deﬁned as three times the gross
domestic product (GDP) per capita; for referencing purposes, a
mean of 3 years is used. Several other countries apply an implicit
threshold, which is usually between two to three times the GDP
per capita (Hungary and The Netherlands). In some countries, the
applied threshold value differs on the basis of the type of
intervention or a threshold is not deﬁned at all (France, Germany,
Romania, and the Czech Republic).
Signiﬁcant differences across analyzed countries were found
in data availability. The survey found that in WE countries, data
can be acquired more easily (although not free of charge) than in
CEE countries because WE countries’ databases on drug prices/
reimbursement are available and recent. Data on overall mortal-
ity are usually available with a 1- to 2-year delay. Selected data on
speciﬁc mortality and morbidity can be estimated from govern-
mental sources; however, databases do not include all medical
conditions. Health insurance funds usually do not open their data
to the public regardless of the considered region. Insurer’s data
can usually be obtained only from the published literature
(Poland and the Czech Republic) or purchased (Hungary). Patient
registries are an important source for assessing effectiveness. In
WE countries, registries are more accessible (the United Kingdom,
The Netherlands, France, Sweden, and Germany) than in CEE
countries, where registries are either not available (Romania and
Hungary) or not easily accessible (Poland, the Czech Republic, and
Slovakia). In the two latter countries, some initiatives are cur-
rently underway to enable better utilization and broader access
for speciﬁed HTA bodies and manufacturers.
Hospital records on epidemiology and patient-reported out-
comes are available with restrictions in the United Kingdom,
France, and The Netherlands (hospital products only). In the CEE
countries, hospital data availability depends on therapeutic area
(Hungary), can be obtained by retrospective studies from medical
charts and/or hospital information systems (Poland and the
Czech Republic), or by expert interviews (Hungary).
For resource use utilization and costs, there are some sources
of information available. In all WE countries, recent data are
available and free of charge for inpatient data, outpatient fees
and reimbursement for procedures, testing, and other diagnostic
methods. In CEE countries, data for diagnostic tests and out-
patient visits can be derived from published price-lists (annually
in the Czech Republic, occasionally in Poland), and in speciﬁc
circumstances from insurance funds (Hungary and Slovakia) or
not available at all (Romania). Obtaining information from insur-
ance funds—charged amounts for health care services—is stated
as “difﬁcult” or “unavailable” across all assessed countries.Table 2 – Steps usually taken to overcome missing data
Countries Ways to o
Own epidemiology
study
Physician
surveys
The Netherlands ✓ ✓
The United Kingdom ✓ ✓
Sweden ✓
France ✓ ✓
Germany ✓ ✓
Romania ✓ ✓
Poland ✓
Hungary ✓
The Czech Republic ✓ ✓
Slovakia ✓ ✓
Total 7 10In WE and CEE countries, the following items are perceived as
missing for conducting high-proﬁle HE analyses:for
ver
PaSpeciﬁc cost and resource-use data linked to diagnosis (Roma-
nia, Slovakia, and partly Sweden) Local quality-of-life data (The Netherlands, the United King-
dom, and the Czech Republic) Local data on the epidemiology of disease (the United King-
dom, Romania, and Slovakia) Accessibility of registry data (Hungary)
 Local HE data (France, Poland, and Slovakia)
 Lack of data on rare diseases (most of the participants
including the United Kingdom and The Netherlands)
Because pharmaceutical companies have to overcome the
hurdles that exist, they often have to initiate their own research
(Table 2).Discussion
Limited ﬁnancial resources for health care are a hot topic across
the EU. A number of initiatives mainly affecting the pharmaceut-
ical sector have been undertaken to increase the transparency of
pricing and reimbursement processes [1], while others focus on
best practices in HTA [2]. The “Joint EC (ECFIN)-EPC Report on
Health Systems” and the Economic Policy Committee have
stressed the need to keep health care budgets under control by
rational use of pharmaceuticals [3].
Almost all EU member states regulate pharmaceutical mar-
kets to a certain extent. These regulations mainly focus on
pricing, reimbursement, market entry, and/or expenditure con-
trol. HTA is used to guide pricing and reimbursement decisions.
HTA is now used in most of the EU member states as a valuable
tool for evidence-based decisions to identify health care inter-
ventions perceived to offer greatest value for money. Even in
countries not yet following a systematic HTA approach (e.g., the
Czech Republic and Romania), steps are undertaken to introduce
a regular HTA assessment and appraisal process. Although
clinical data might be transferable across Europe, economic data
have to reﬂect speciﬁc situations of individual member states and
therefore usually cannot be nor should be transferred even from
countries with similar socioeconomic attributes. Therefore, local
data are needed to obtain robust economic analyses.
Examples from several countries show that building capacity
for HTA implementation is an important but costly and long-
term process. In Hungary, such a process started in the mid-1990shealth economic analyses.
come limited data sources
tient chart
reviews
Purchasing data from
third party
Organize own
registries
✓ ✓ ✓
✓ ✓ ✓
✓ ✓
✓ ✓ ✓
✓ ✓ ✓
✓ ✓
✓
✓ ✓
✓ ✓ ✓
✓ ✓ ✓
9 9 7
V A L U E I N H E A L T H R E G I O N A L I S S U E S 4 C ( 2 0 1 4 ) 5 3 – 5 756and by 2010 the number of trained and experienced professionals
exceeded 200 [4].
Because of the recent HTA developments across the EU, we
conducted a survey of ofﬁcial requirements and available local
data to fulﬁll these requirements, among 10 EU countries, cover-
ing both WE and CEE countries. We speciﬁcally also focused on
the role of HE assessments (CE and BI) in the countries included
in the survey. We found that in our sample economic require-
ments are much stronger in CEE countries (mandatory in all) than
in WE countries (only three countries with mandatory economic
evaluation for innovative drugs). In the survey, we did not focus
on qualitative aspects of economic applications and assessments;
however, the published literature stresses the limited number of
trained HTA professionals in CEE countries, lack of local post-
graduate university training opportunities, and calls on more
action to ensure sufﬁcient HTA capacity [5]. The high unmet need
in this respect becomes even more urgent because all CEE
countries and most of the WE countries (except Germany) have
included HE in their legislation. A closer cooperation with WE
universities might be the ﬁrst step for CEE countries to obtain
expertise not only in economic evaluations but also in clinical
aspects of HTA. A recent publication compared 48 Polish and
Scottish HTA recommendations on the same drugs assessed in
the period January through December 2008 [6]. A higher propor-
tion of drug technologies obtained a negative recommendation in
Poland (19 of 48) than in Scotland (11 of 48). Surprisingly, clinical
reasons for rejection (poor safety and efﬁcacy) dominated deci-
sions in Poland, while economic aspects were most often stated
in Scotland. The author herself did not have a clear explanation
for this phenomenon; however, she concludes that improvement
in Polish methodological guidelines, related to clinical effective-
ness issues, is needed to capture patient subpopulations that
might beneﬁt from interventions if analyzed separately.
The WTP threshold and outcome measures are other aspects
with large variations across the EU. Most of the CEE countries
refer to QALY as the appropriate and preferred outcome, showing
a strong orientation to the National Institute for Health and Care
Excellence and the Scottish Medicines Consortium. Latest devel-
opments in the United Kingdom with the planned introduction of
“value-based-pricing” as well as the “QALY controversy” dis-
cussed recently might question the strict QALY orientation [7].
In countries with an existing threshold value or range, usually
the approach connected to GDP is used. It is, however, usually
lower than the three times GDP per capita recommended by the
World Health Organization [8,9] (for poor countries). Two coun-
tries in the CEE (Poland and Slovakia) even have a threshold
range strictly incorporated in their legislation. In several WE and
CEE countries (France, Germany, Romania, and the Czech Repub-
lic), no ofﬁcial threshold was deﬁned although CE analysis is
sometimes mandatory for innovative drugs during the reim-
bursement process (the Czech Republic and Romania). Experience
from different jurisdictions reveals the difﬁculty in justifying a
single explicit threshold without denying the option to incorpo-
rate other dimensions (as societal preferences) into the pricing
and reimbursement process [10,11]. Even if a WTP range is
considered, it remains questionable whether equity of access to
medicines across citizens can be ensured in an EU environment
with differing national economic output and uniﬁed pricing
strategies set by manufacturers. An analysis, derived from phase
III trials, focusing on modern oncology drugs was recently
performed in the Czech Republic [12]. Only 4 of the 14 assessed
drugs (mainly biological therapies) met the implicit threshold for
cost per life-year-gained.
One of the signiﬁcant differences found in our survey related
to data availability. Findings show that access to data seems to be
easier in WE countries than in CEE countries, although areas for
improvement are found across the whole EU. Epidemiologicaldata, if available, usually have delayed publication, and even
health insurance funds do not present sufﬁcient information to
be used for economic analyses. Registries seem to be more easily
accessible in WE countries, whereas in the CEE countries they are
either not available or not easy to access. Exceptions exist such as
the Czech National Oncology Registry, which provides a lot of
useful information especially on epidemiology and helps to
predict expenditure dynamics for oncology treatments. In con-
trast to WE countries, little effort has been undertaken by
governments in the CEE countries to establish registries and
use them to show the real-life effectiveness of medications
beyond a clinical trial setting for multitechnology appraisals.
One of the reasons might be the absence of ﬁnancial support to
create and conduct registries, which are mainly ﬁnanced by the
pharmaceutical industry, together with the complexity of the
process [13,14].
Our survey tried to capture differences and similarities across
selected EU countries from WE and CEE countries regarding HTA,
focusing on HE, which is evolving rapidly in CEE countries.
However, our study has several limitations. One of them is the
narrow time frame of the survey (last quarter of 2012). In the
Results section, we mentioned that CE guidelines are not in place
in the Czech Republic and Romania. Meanwhile, a guideline was
published and has been effective since February 2013 in the
Czech Republic, and Romania is currently exploring possibilities
to introduce certain HTA criteria. A further explanation as to why
Pan-European decisions about medical technologies are not
realistic lies in differences in the ﬁnancing and organization of
health care systems and speciﬁc local factors.
Despite the differences, there are several efforts that could be
undertaken at the European level and adopted locally. We
suggest that clinical HTAs in particular could to a large extent
be transferable among countries. A current initiative by
EUnetHTA - Joint Action 2, which covers the period of 2012 to
2015, facilitates international collaboration and strengthens the
practical application of HTA tools and approaches. This repre-
sents a valuable opportunity for CEE countries to get involved in
HTA processes and learn from HTA-mature countries.
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